Vivimed Labs Limited has informed the Exchange regarding Board meeting held on August 13, 2025.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivimed Labs reported weak Q1 FY26 results with standalone revenue falling to Rs 179.43 million from Rs 246.36 million a year ago (~27% decline). The company posted a standalone loss of Rs 54.95 million and consolidated loss of Rs 54.93 million for the quarter ended June 30, 2025. All loan accounts have been classified as Non-Performing Assets (NPA) by banks, with total defaults of Rs 3,748.22 million as on June 30, 2025; the company is negotiating a settlement with lenders. The auditor issued a qualified (modified) opinion on both standalone and consolidated results because the company did not accrue Rs 149.83 million in interest expenses — if recognized, the adjusted standalone loss would swell to Rs 204.78 million and consolidated net worth would turn negative at Rs (556.45) million. The board also approved re-appointment of directors and pledged overseas securities to raise funds for debt repayment.
This is a negative signal for shareholders — NPA status on all loans, a qualified audit opinion, persistent losses, and revenue decline together raise serious solvency concerns. Stock is likely to remain under pressure until the company resolves its bank defaults and lender settlement.